Dyshidrotic eczema and seborrheic dermatitis-like eczematous eruption following intravenous immunoglobulin therapy.

Abstract

Intravenous immunoglobulin (IVIg) is increasingly used for the treatment of inflammatory and autoimmune diseases. Although skin reactions to IVIg therapy are usually minor, rare, and not life-threatening, dermatologists need to recognize the nature of these adverse reactions. We describe a 33-year-old man suffering from demyelinating polyneuropathy who developed dyshidrotic eczema on the palms and flaky grayish-white scales on an erythematous base on his face after the administration of IVIg.

• Authors: Zennure Takci, Gulcin Guler Simsek, Hatice Uzuner, Atiye Akbayrak, Havva Yıldız Seckin, Ayse Serap Karadag
• Journal: Dermatologic therapy (Dermatol Ther) Vol. 33 Issue 6 Pg. e14147 (11 2020) ISSN: 1529-8019 [Electronic] United States
• PMID: 32767429 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2020 Wiley Periodicals LLC.

Chemical References

• Immunoglobulins, Intravenous

Topics

• Adult
• Dermatitis, Seborrheic
• Eczema (chemically induced, diagnosis, therapy)
• Eczema, Dyshidrotic (chemically induced, diagnosis)
• Exanthema
• Humans
• Immunoglobulins, Intravenous (adverse effects)
• Male